A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

A Phase 1, Non-randomized, Open-label, Parallel-group Single-dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Intravenous Rivipansel (Pf-06460031) In Subjects With Moderate Hepatic Impairment And In Healthy Subjects With Normal Hepatic Function

The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK and safety.

Inclusion Criteria:

• Female subjects of non-childbearing potential or male subjects

  • Body Mass Index (BMI) of 17.5 to 40.0 kg/m2
  • Normal Hepatic function for the healthy subjects
  • Stable Hepatic Impairment for the subjects with moderate hepatic impairment

Exclusion Criteria:

• Treatment with an investigational drug within 30 days of the dose of study medication
• Pregnant females, breastfeeding female subjects and male subjects with partners currently pregnant
• Use of herbal supplements in the 28 days prior to the dose of study medication
• Blood donation (excluding plasma donation) of approximately 1 pint or more within 56 days prior to study medication
• A positive urine drug screen for illicit drugs